Chongqi Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chongqi Tu has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Hong Duan
Sichuan University
19 shared publications Li Min
Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China
16 shared publicationsYong Zhou
Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China
13 shared publicationsHui Zhang
11 shared publications- Fuxing Pei
Department of Orthopaedics and Orthopaedic Research Institute, West China Hospital, Sichuan University, Chengdu, People's Republic of China
9 shared publications - Yue Fang
Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
9 shared publications
Latest Publications
- 15 October 2023
- Vol. 37 (10) , 1183-1189
3D打印定制半骨盆假体在组配式半骨盆假体无菌性松动或螺钉断裂患者翻修中的应用
探讨组配式半骨盆假体无菌性松动或螺钉断裂患者采用3D打印定制半骨盆假体进行翻修的有效性。 2017年2月—2020年1月,对11例组配式半骨盆假体无菌性松动或螺钉断裂患者,采用3D打印定制半骨盆假体进行翻修术。男7例,女4例;年龄25~60岁,平均44岁。初次手术均为肿瘤整块切除并采用组配式半骨盆假体重建、自体股骨头移植。根据Enneking骨盆分区系统,Ⅰ+Ⅱ区切除8例,Ⅰ+Ⅱ+Ⅲ区切除3例。初次手术至该次翻修手术间隔14.3~66.2个月,平均35.8个月。记录手术时间、术中出血量以及并发症发生情况;初次术后6个月、翻修术前以及末次随访时,采用美国骨与软组织肿瘤协会(MSTS)评分及Harris评分评价下肢功能恢复情况;末次随访时记录患者无支具辅助下无痛步行距离。初次术后1个月、翻修术前和翻修术后1个月摄X线片,测算健患侧体质量力臂差值和髋臼杯高度差值,以评估髋臼位置;末次随访时,以数字化X线体层摄影评估假体-骨整合情况及有无无菌性松动发生。 手术时间182.6~238.4 min,平均197.4 min;术中出血量400~860 mL,平均550.0 mL。术后切口均Ⅰ期愈合,无深部感染、髋关节脱位、神经损伤及血管相关不良事件等并发症发生。末次随访时,MSTS评分及Harris评分较初次术后6个月及翻修术前均提高,而翻修术前较初次术后6个月降低,差异均有统计学意义(PPP>0.05)。所有假体与骨整合良好,无假体无菌性松动或螺钉断裂发生。 组配式半骨盆假体置换术后发生假体无菌性松动或螺钉断裂患者,采用3D打印定制半骨盆假体翻修能重建骨盆环完整性,恢复正常力学传导。术后早期行恰当康复训练能够最大限度恢复患者肢体功能、减轻行走时疼痛、降低并发症发生率。
- 15 October 2023
- Vol. 37 (10) , 1183-1189
3D打印定制半骨盆假体在组配式半骨盆假体无菌性松动或螺钉断裂患者翻修中的应用
探讨组配式半骨盆假体无菌性松动或螺钉断裂患者采用3D打印定制半骨盆假体进行翻修的有效性。 2017年2月—2020年1月,对11例组配式半骨盆假体无菌性松动或螺钉断裂患者,采用3D打印定制半骨盆假体进行翻修术。男7例,女4例;年龄25~60岁,平均44岁。初次手术均为肿瘤整块切除并采用组配式半骨盆假体重建、自体股骨头移植。根据Enneking骨盆分区系统,Ⅰ+Ⅱ区切除8例,Ⅰ+Ⅱ+Ⅲ区切除3例。初次手术至该次翻修手术间隔14.3~66.2个月,平均35.8个月。记录手术时间、术中出血量以及并发症发生情况;初次术后6个月、翻修术前以及末次随访时,采用美国骨与软组织肿瘤协会(MSTS)评分及Harris评分评价下肢功能恢复情况;末次随访时记录患者无支具辅助下无痛步行距离。初次术后1个月、翻修术前和翻修术后1个月摄X线片,测算健患侧体质量力臂差值和髋臼杯高度差值,以评估髋臼位置;末次随访时,以数字化X线体层摄影评估假体-骨整合情况及有无无菌性松动发生。 手术时间182.6~238.4 min,平均197.4 min;术中出血量400~860 mL,平均550.0 mL。术后切口均Ⅰ期愈合,无深部感染、髋关节脱位、神经损伤及血管相关不良事件等并发症发生。末次随访时,MSTS评分及Harris评分较初次术后6个月及翻修术前均提高,而翻修术前较初次术后6个月降低,差异均有统计学意义(PPP>0.05)。所有假体与骨整合良好,无假体无菌性松动或螺钉断裂发生。 组配式半骨盆假体置换术后发生假体无菌性松动或螺钉断裂患者,采用3D打印定制半骨盆假体翻修能重建骨盆环完整性,恢复正常力学传导。术后早期行恰当康复训练能够最大限度恢复患者肢体功能、减轻行走时疼痛、降低并发症发生率。
- 15 October 2023
- Vol. 37 (10) , 1190-1197
生物型同种异体骨-假体复合物重建股骨近端肿瘤性骨缺损的远期疗效
探讨生物型同种异体骨-假体复合物(allograft-prosthesis composite,APC)重建股骨近端肿瘤性骨缺损的远期疗效。 回顾分析2007年6月—2014年3月21例行股骨近端骨肿瘤切除并生物型APC重建的患者临床资料。男9例,女12例;年龄19~54岁,平均33.2岁。肿瘤类型:骨巨细胞瘤9例,骨肉瘤5例,骨母细胞瘤4例,软骨肉瘤2例,多形性未分化肉瘤1例。13例良性骨肿瘤Enneking 分期均为3期;8例恶性骨肿瘤根据美国癌症联合委员会(AJCC)分级系统,ⅡB级7例、ⅡA级1例。其中7例为复发后再次手术,其余患者均为初次手术。8例合并病理性骨折。术前Harris髋关节评分(HHS)为43(30,49)分,美国骨与软组织肿瘤协会(MSTS)评分为(9.1±3.5)分。术中截骨长度为80~154 mm,平均110 mm。术后1年和末次随访时,采用HHS评分以及MSTS评分评估患者关节功能状态,以臀中肌力量评分评估外展肌功能。术后1、3、6、9、12个月以及之后每年影像学复查,观察骨-骨界面愈合以及骨质吸收情况。记录术中及术后随访并发症发生情况。 患者均获随访,随访时间84~163个月,平均123.5个月。术后1年及末次随访时 MSTS评分、HHS评分均较术前提高(PP>0.05)。影像学复查示患者骨-骨界面均愈合,愈合时间5~10个月,平均7.6个月;末次随访时患者均存在骨吸收,其中重度11例、中度4例、轻度6例;骨吸收部位涉及Gruen 1、2和7区。并发症包括10例骨折以及1例假体断裂。随访期间3例局部复发,3例发生肺转移。 生物型APC是重建股骨近端肿瘤性骨缺损可靠方法,具有较好远期疗效,在骨-骨界面愈合上具有明显优势。
- 15 October 2023
- Vol. 37 (10) , 1190-1197
生物型同种异体骨-假体复合物重建股骨近端肿瘤性骨缺损的远期疗效
探讨生物型同种异体骨-假体复合物(allograft-prosthesis composite,APC)重建股骨近端肿瘤性骨缺损的远期疗效。 回顾分析2007年6月—2014年3月21例行股骨近端骨肿瘤切除并生物型APC重建的患者临床资料。男9例,女12例;年龄19~54岁,平均33.2岁。肿瘤类型:骨巨细胞瘤9例,骨肉瘤5例,骨母细胞瘤4例,软骨肉瘤2例,多形性未分化肉瘤1例。13例良性骨肿瘤Enneking 分期均为3期;8例恶性骨肿瘤根据美国癌症联合委员会(AJCC)分级系统,ⅡB级7例、ⅡA级1例。其中7例为复发后再次手术,其余患者均为初次手术。8例合并病理性骨折。术前Harris髋关节评分(HHS)为43(30,49)分,美国骨与软组织肿瘤协会(MSTS)评分为(9.1±3.5)分。术中截骨长度为80~154 mm,平均110 mm。术后1年和末次随访时,采用HHS评分以及MSTS评分评估患者关节功能状态,以臀中肌力量评分评估外展肌功能。术后1、3、6、9、12个月以及之后每年影像学复查,观察骨-骨界面愈合以及骨质吸收情况。记录术中及术后随访并发症发生情况。 患者均获随访,随访时间84~163个月,平均123.5个月。术后1年及末次随访时 MSTS评分、HHS评分均较术前提高(PP>0.05)。影像学复查示患者骨-骨界面均愈合,愈合时间5~10个月,平均7.6个月;末次随访时患者均存在骨吸收,其中重度11例、中度4例、轻度6例;骨吸收部位涉及Gruen 1、2和7区。并发症包括10例骨折以及1例假体断裂。随访期间3例局部复发,3例发生肺转移。 生物型APC是重建股骨近端肿瘤性骨缺损可靠方法,具有较好远期疗效,在骨-骨界面愈合上具有明显优势。
- 15 August 2023
- Vol. 37 (8) , 970-977
3D打印股骨近端弧形柄仿生假体重建股骨中上段超极限骨缺损保髋治疗的中期临床疗效
探索3D打印股骨近端弧形柄仿生假体的设计要点,评估将其应用于重建股骨中上段超极限骨缺损的手术要点和中期临床疗效。 2015年10月—2021年1月,17例患者接受了3D打印股骨干弧形柄仿生假体重建。男11例,女6例;年龄10~76岁,平均30.1岁。骨肉瘤9例,尤文肉瘤4例,软骨肉瘤2例,脂肪肉瘤1例,肌纤维母细胞瘤1例。病程5~14个月,平均9.5个月。Enneking分期:ⅡB期16例,ⅢB期1例。根据X线片测量术前股骨头中心到人体正中线和髋臼顶点的距离,术后即刻及末次随访时弧形柄尖端到人体正中线和髋臼顶点的距离,以及术前、术后即刻和末次随访时的颈干角。通过X线片、CT和断层融合成像技术(Tomosynthesis-Shimadzu metal artefact reduction technology,T-SMART)评估骨-假体界面的骨整合状况及假体表面骨长入情况。随访患者生存状态、有无局部复发或远处转移,术后并发症发生情况。手术前后通过肌肉骨骼肿瘤学会(MSTS)评分评价下肢功能恢复情况,疼痛视觉模拟评分(VAS)评价疼痛缓解情况。 患者股骨切除长度为(163.1±57.5)mm,剩余股骨近端长度为(69.6±9.3)mm,股骨切除长度/股骨总长度百分比为38.7%±14.6%。17例患者均获随访,随访时间25~86个月,平均58.1个月。随访期间1例患者于术后46个月死于肺转移,余16例患者无瘤生存。均未发生假体周围感染、切口延迟愈合、假体无菌性松动、假体断裂、假体周围骨折等并发症。X线片和T-SMART评估未发现植入假体柄周围微动磨损,也无明显放射性透亮带,并且在所有柄中都发现了骨-假体界面上骨向内生长的射线学迹象。术后即刻及末次随访时弧形柄尖端到人体正中线和髋臼顶点的距离分别与术前股骨头中心到人体正中线和髋臼顶点的距离比较,差异无统计学意义(P>0.05);术后即刻和末次随访间上述指标比较差异亦无统计学意义(P>0.05)。手术前后各时间点颈干角比较差异均无统计学意义(P>0.05)。末次随访时患者MSTS评分为(26.1±1.2)分,VAS评分为(0.1±0.5)分,均较术前 [分别为(19.4±2.1)分和(5.7±1.0)分] 显著改善(t=14.735,Pt=21.301,P<0.001)。末次随访时,患者均无需借助拐杖或其他助行器行走。 3D打印股骨近端弧形柄仿生假体是股骨中上段恶性肿瘤切除术后超极限骨缺损重建的有效方法,术中操作可靠,术后下肢功能恢复满意,并发症发生率低。
- 15 August 2023
- Vol. 37 (8) , 970-977
3D打印股骨近端弧形柄仿生假体重建股骨中上段超极限骨缺损保髋治疗的中期临床疗效
探索3D打印股骨近端弧形柄仿生假体的设计要点,评估将其应用于重建股骨中上段超极限骨缺损的手术要点和中期临床疗效。 2015年10月—2021年1月,17例患者接受了3D打印股骨干弧形柄仿生假体重建。男11例,女6例;年龄10~76岁,平均30.1岁。骨肉瘤9例,尤文肉瘤4例,软骨肉瘤2例,脂肪肉瘤1例,肌纤维母细胞瘤1例。病程5~14个月,平均9.5个月。Enneking分期:ⅡB期16例,ⅢB期1例。根据X线片测量术前股骨头中心到人体正中线和髋臼顶点的距离,术后即刻及末次随访时弧形柄尖端到人体正中线和髋臼顶点的距离,以及术前、术后即刻和末次随访时的颈干角。通过X线片、CT和断层融合成像技术(Tomosynthesis-Shimadzu metal artefact reduction technology,T-SMART)评估骨-假体界面的骨整合状况及假体表面骨长入情况。随访患者生存状态、有无局部复发或远处转移,术后并发症发生情况。手术前后通过肌肉骨骼肿瘤学会(MSTS)评分评价下肢功能恢复情况,疼痛视觉模拟评分(VAS)评价疼痛缓解情况。 患者股骨切除长度为(163.1±57.5)mm,剩余股骨近端长度为(69.6±9.3)mm,股骨切除长度/股骨总长度百分比为38.7%±14.6%。17例患者均获随访,随访时间25~86个月,平均58.1个月。随访期间1例患者于术后46个月死于肺转移,余16例患者无瘤生存。均未发生假体周围感染、切口延迟愈合、假体无菌性松动、假体断裂、假体周围骨折等并发症。X线片和T-SMART评估未发现植入假体柄周围微动磨损,也无明显放射性透亮带,并且在所有柄中都发现了骨-假体界面上骨向内生长的射线学迹象。术后即刻及末次随访时弧形柄尖端到人体正中线和髋臼顶点的距离分别与术前股骨头中心到人体正中线和髋臼顶点的距离比较,差异无统计学意义(P>0.05);术后即刻和末次随访间上述指标比较差异亦无统计学意义(P>0.05)。手术前后各时间点颈干角比较差异均无统计学意义(P>0.05)。末次随访时患者MSTS评分为(26.1±1.2)分,VAS评分为(0.1±0.5)分,均较术前 [分别为(19.4±2.1)分和(5.7±1.0)分] 显著改善(t=14.735,Pt=21.301,P<0.001)。末次随访时,患者均无需借助拐杖或其他助行器行走。 3D打印股骨近端弧形柄仿生假体是股骨中上段恶性肿瘤切除术后超极限骨缺损重建的有效方法,术中操作可靠,术后下肢功能恢复满意,并发症发生率低。
- Open Access
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e25262
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient
Introduction: Myxofibrosarcoma (MFS) is a locally aggressive tumor and has the potential to be fatal because of distant metastasis. Immunotherapy targeting either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently shown a curative effect on multiple cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. Although the immunotherapy has been applied in sarcoma, there is little information about the efficiency to treat metastatic MFS. Patient concerns: A 42-year-old male presented to the clinic with a mass in the left thigh. Mass resection and ligament replacement surgery were performed. Diagnoses: The patient was diagnosed as high-grade MFS (federation nationale des centres de lutte contre le cancer, Grade 3) with pulmonary metastasis. Interventions: In the past few years, he was treated with surgery, chemoradiotherapy, and Anlotinib (an angiogenesis inhibitor), but the metastatic lesion continued to progress. About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts. Thus, he received Camrelizumab (PD-1 inhibitor). Outcomes: Six months after the initiating immunotherapy of Camrelizumab, the size of pulmonary lesions showed marked shrinkage, indicating a partial response. After a follow-up of 18 months, the patient remained in good condition without progressive disease. Conclusion: This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
- 26 March 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (12) , e25262
Open AccessRemarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient
Introduction: Myxofibrosarcoma (MFS) is a locally aggressive tumor and has the potential to be fatal because of distant metastasis. Immunotherapy targeting either programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently shown a curative effect on multiple cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma. Although the immunotherapy has been applied in sarcoma, there is little information about the efficiency to treat metastatic MFS. Patient concerns: A 42-year-old male presented to the clinic with a mass in the left thigh. Mass resection and ligament replacement surgery were performed. Diagnoses: The patient was diagnosed as high-grade MFS (federation nationale des centres de lutte contre le cancer, Grade 3) with pulmonary metastasis. Interventions: In the past few years, he was treated with surgery, chemoradiotherapy, and Anlotinib (an angiogenesis inhibitor), but the metastatic lesion continued to progress. About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts. Thus, he received Camrelizumab (PD-1 inhibitor). Outcomes: Six months after the initiating immunotherapy of Camrelizumab, the size of pulmonary lesions showed marked shrinkage, indicating a partial response. After a follow-up of 18 months, the patient remained in good condition without progressive disease. Conclusion: This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
- Open Access
- 1 March 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (5) , 416
Prolonged balloon occlusion of the lower abdominal aorta during pelvic or sacral tumor resection
Background: To explore the efficacy of lower abdominal aorta balloon occlusion technology in pelvis and sacral tumor surgery and to assess the safety of prolonged balloon occlusion. Methods: From January 2008 to January 2017, 81 patients were diagnosed with sacrum or pelvic tumor and underwent surgery in our institution. Balloon catheters were placed through the femoral artery to occlude the abdominal aorta of the pelvic tumor and sacrum region undergoing tumor resection. These patients were divided into two group based on single balloon blocking time. Group A had a balloon blocking time of 60 minutes or less, and group B had a balloon occlusion time greater than 60 minutes. The patients in the two groups were compared with regards to operation time, intraoperative blood loss, blood transfusion volume, average length of hospital stay, and postoperative complications. Results: No balloon displacement or leakage of the abdominal aorta occurred during the operations. The difference in operation time between the two groups was statistically significant (P≤0.05), and the differences in intraoperative blood loss, blood transfusion volume, and average hospital stay between groups A and B were not significant (P>0.05). The incidence of postoperative complications was 12% in group A, and 22.6% in group B, with no statistically significant differences (P>0.05). Conclusions: Prolonged balloon occlusion was safe and effective in the surgical treatment of complicated pelvic and sacral tumors. It did not increase the incidence of postoperative complications such as distal limb paralysis, arterial thrombosis, or ischemic necrosis.
- 1 March 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (5) , 416
Open AccessProlonged balloon occlusion of the lower abdominal aorta during pelvic or sacral tumor resection
Background: To explore the efficacy of lower abdominal aorta balloon occlusion technology in pelvis and sacral tumor surgery and to assess the safety of prolonged balloon occlusion. Methods: From January 2008 to January 2017, 81 patients were diagnosed with sacrum or pelvic tumor and underwent surgery in our institution. Balloon catheters were placed through the femoral artery to occlude the abdominal aorta of the pelvic tumor and sacrum region undergoing tumor resection. These patients were divided into two group based on single balloon blocking time. Group A had a balloon blocking time of 60 minutes or less, and group B had a balloon occlusion time greater than 60 minutes. The patients in the two groups were compared with regards to operation time, intraoperative blood loss, blood transfusion volume, average length of hospital stay, and postoperative complications. Results: No balloon displacement or leakage of the abdominal aorta occurred during the operations. The difference in operation time between the two groups was statistically significant (P≤0.05), and the differences in intraoperative blood loss, blood transfusion volume, and average hospital stay between groups A and B were not significant (P>0.05). The incidence of postoperative complications was 12% in group A, and 22.6% in group B, with no statistically significant differences (P>0.05). Conclusions: Prolonged balloon occlusion was safe and effective in the surgical treatment of complicated pelvic and sacral tumors. It did not increase the incidence of postoperative complications such as distal limb paralysis, arterial thrombosis, or ischemic necrosis.
- 15 June 2020
- Vol. 34 (6) , 744-750
肩胛带韧带样纤维瘤华西分区指导外科治疗的远期疗效观察
评估肩胛带韧带样纤维瘤(desmoid-type fibromatosis,DTF)华西分区指导外科治疗的远期临床疗效。 回顾分析 2003 年 6 月—2016 年 12 月收治的 32 例肩胛带 DTF 患者临床资料,男 14 例,女 18 例;年龄 14~56 岁,平均 36.8 岁。肿瘤最大径 7~19 cm,平均 11.1 cm。根据肩胛带 DTF 华西分区,肿瘤位于 Ⅰ 区 4 例、Ⅱ 区 3 例、Ⅲ 区 6 例、Ⅳ 区 3 例、Ⅰ+Ⅱ 区 5 例、Ⅱ+Ⅲ 区 5 例、Ⅰ+Ⅱ+Ⅲ 区 6 例。根据肩胛带 DTF 华西分区及血管神经受累情况,12 例采用前路手术(A 组),14 例采取后路手术(B 组),6 例采用前-后联合入路手术(C 组)。记录并比较 3 组患者 1993 美国骨肿瘤学会评分系统(MSTS93) 评分(包括疼痛、肢体功能、满意度、手的位置、手灵活度、举物能力 6 方面)、日本骨科协会(JOA)评分、肩关节活动度(包括前屈、后伸、外展、内收)及并发症发生情况。 32 例患者均获随访,随访时间 30~190 个月,平均 94.6 个月。随访期间共 5 例(15.6%)患者发生并发症,其中 A 组 2 例(16.6% )、B 组 2 例(14.3%)、C 组 1 例(16.6%),各组并发症发生率比较差异均无统计学意义(P=1.000)。至末次随访时,共 4 例(12.5%)患者肿瘤复发,其中 A 组 1 例(8.3%)、B 组 2 例(14.3%)、C 组 1 例(16.6%),各组复发率比较差异均无统计学意义(P=1.000)。末次随访时,A、B 组 MSTS93 评分的疼痛、肢体功能、满意度、手灵活性、手的位置评分及总分均显著优于 C 组(P0.05);C 组举物能力评分显著低于 A 组(P0.05)。A、B 组 JOA 评分及肩关节前屈、后伸、外展、内收活动度均显著优于 C 组(P0.05)。 根据肩胛带 DTF 华西分区选择适当的手术入路,充分暴露并完整切除肿瘤,取得了较满意的远期临床疗效。
- 15 June 2020
- Vol. 34 (6) , 744-750
肩胛带韧带样纤维瘤华西分区指导外科治疗的远期疗效观察
评估肩胛带韧带样纤维瘤(desmoid-type fibromatosis,DTF)华西分区指导外科治疗的远期临床疗效。 回顾分析 2003 年 6 月—2016 年 12 月收治的 32 例肩胛带 DTF 患者临床资料,男 14 例,女 18 例;年龄 14~56 岁,平均 36.8 岁。肿瘤最大径 7~19 cm,平均 11.1 cm。根据肩胛带 DTF 华西分区,肿瘤位于 Ⅰ 区 4 例、Ⅱ 区 3 例、Ⅲ 区 6 例、Ⅳ 区 3 例、Ⅰ+Ⅱ 区 5 例、Ⅱ+Ⅲ 区 5 例、Ⅰ+Ⅱ+Ⅲ 区 6 例。根据肩胛带 DTF 华西分区及血管神经受累情况,12 例采用前路手术(A 组),14 例采取后路手术(B 组),6 例采用前-后联合入路手术(C 组)。记录并比较 3 组患者 1993 美国骨肿瘤学会评分系统(MSTS93) 评分(包括疼痛、肢体功能、满意度、手的位置、手灵活度、举物能力 6 方面)、日本骨科协会(JOA)评分、肩关节活动度(包括前屈、后伸、外展、内收)及并发症发生情况。 32 例患者均获随访,随访时间 30~190 个月,平均 94.6 个月。随访期间共 5 例(15.6%)患者发生并发症,其中 A 组 2 例(16.6% )、B 组 2 例(14.3%)、C 组 1 例(16.6%),各组并发症发生率比较差异均无统计学意义(P=1.000)。至末次随访时,共 4 例(12.5%)患者肿瘤复发,其中 A 组 1 例(8.3%)、B 组 2 例(14.3%)、C 组 1 例(16.6%),各组复发率比较差异均无统计学意义(P=1.000)。末次随访时,A、B 组 MSTS93 评分的疼痛、肢体功能、满意度、手灵活性、手的位置评分及总分均显著优于 C 组(P0.05);C 组举物能力评分显著低于 A 组(P0.05)。A、B 组 JOA 评分及肩关节前屈、后伸、外展、内收活动度均显著优于 C 组(P0.05)。 根据肩胛带 DTF 华西分区选择适当的手术入路,充分暴露并完整切除肿瘤,取得了较满意的远期临床疗效。
- Open Access
- 22 August 2018
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 1 (2) , 88-96
First application of 3D design custom-made uncemented prosthetic stem for distal femoral cemented megaprosthesis revision
Objectives: 3D design, which is widely used in orthopedics, can be applied for precise distal femoral megaprosthetic revision. This research aimed to present and evaluate the design, perioperative management, and mid-term clinical outcomes of a 3D design custom-made uncemented prosthetic stem.Methods: Between January 2014 and January 2016, seven patients received 3D design custom-made uncemented prosthetic stem revision at our institution. Clinical records and radiographs were evaluated retrospectively.Results: There were no hardware-related complications during the follow-up (average 24.3 months; range 24–48 months). The average Musculoskeletal Tumor Society (MSTS) score at the last follow-up after revision (27.7 points, range 25–28 points) was significantly higher than that before (16.0 points, range 13–18 points). In addition, the range of motion (ROM) of the affected knee, and the scores of pain, function, emotional acceptance, support, walking and gait all improved significantly. The antecurvature radian of the revision stem averaged at 3.6°. Of the seven patients, three received femoral stem revision and four received revision of the femoral stem and the femoral component; three of them used longer prostheses than the others. There were no significant differences in function between these two groups at the last follow-up after revision.Conclusion: The 3D design custom-made prosthesis is a typical precision medicine technology in oncologic orthopedics. Characterized by its individually and precisely designed uncemented stem, it offers an alternative option for distal femoral cemented prosthesis revision. Besides the 3D design itself, the perioperative management, especially the techniques for stem implantation, and long-term follow-up are also crucial.
- 22 August 2018
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 1 (2) , 88-96
Open AccessFirst application of 3D design custom-made uncemented prosthetic stem for distal femoral cemented megaprosthesis revision
Objectives: 3D design, which is widely used in orthopedics, can be applied for precise distal femoral megaprosthetic revision. This research aimed to present and evaluate the design, perioperative management, and mid-term clinical outcomes of a 3D design custom-made uncemented prosthetic stem.Methods: Between January 2014 and January 2016, seven patients received 3D design custom-made uncemented prosthetic stem revision at our institution. Clinical records and radiographs were evaluated retrospectively.Results: There were no hardware-related complications during the follow-up (average 24.3 months; range 24–48 months). The average Musculoskeletal Tumor Society (MSTS) score at the last follow-up after revision (27.7 points, range 25–28 points) was significantly higher than that before (16.0 points, range 13–18 points). In addition, the range of motion (ROM) of the affected knee, and the scores of pain, function, emotional acceptance, support, walking and gait all improved significantly. The antecurvature radian of the revision stem averaged at 3.6°. Of the seven patients, three received femoral stem revision and four received revision of the femoral stem and the femoral component; three of them used longer prostheses than the others. There were no significant differences in function between these two groups at the last follow-up after revision.Conclusion: The 3D design custom-made prosthesis is a typical precision medicine technology in oncologic orthopedics. Characterized by its individually and precisely designed uncemented stem, it offers an alternative option for distal femoral cemented prosthesis revision. Besides the 3D design itself, the perioperative management, especially the techniques for stem implantation, and long-term follow-up are also crucial.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e22500
A preliminary study of apatinib in Chinese patients with osteosarcoma.
E22500 Background: Osteosarcoma is the most common malignant tumor of bone that displays hyperproliferative characteristics and high vascularity, making vascular endothelial growth factor receptors (VEGFRs) become promising targets. Apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, shows anti-cancer effects against a broad range of malignancies. This study reported the clinical experience of apatinib in osteosarcoma. Methods: We collected the medical data of osteosarcoma cases who received apatinib for at least one month in our hospital. The objective response rate (ORR), disease control rate (DCR), and 6-month progression-free survival (PFS) and overall survival (OS) rates were evaluated, and the safety profile was observed. The cut-off date of analysis was 01/17/2017. Results: Between May 2015 and Nov 2016, a total of 34 cases received apatinib with informed consent (4 as neoadjuvant, 1 as neoadjuvant and first line, 10 as first line, 15 as second line and 4 as third line). Among them, 18 (52.9%) cases suffered from pulmonary metastases before apatinib administration; 29 (85.3%) patients had an Eastern Cooperative Oncology Group performance status of 1–2. Initial dosages of 250, 425, and 500 mg/d were given to 5 (14.7%), 3 (8.8%), and 26 (76.5%) cases, respectively. Dosage adjustment occurred in only 8 (23.5%) patients. The median duration was 5.9 months (95%CI, 4.5–9.4 months). According to RECIST v1.1, complete response, partial response, stable disease and progressive disease were achieved in 1 (2.9%), 6 (17.6%), 25 (73.5%) and 2 (5.9%) patients, respectively. The ORR was 20.5%, and the DCR was 94.1%. Patients with pulmonary metastases showed a relatively better response to apatinib, as the ORR and DCR were 33.3% and 88.9%, respectively. As for safety analysis, the most 3 common adverse events (AEs) were hand-foot syndrome (HFS) (29, 85.3%), diarrhea (16, 47.1%), and decreased appetite (9, 26.5%). Nine grade III AEs were occurred including 3 HFS, 2 hypertension, 1 diarrhea, 1 oral mucositis, 1 proteinuria and 1 serious peeling. Conclusions: Apatinib seems to be effective in treating osteosarcoma with acceptable safety profile. Perspective clinical studies with adequate sample size are required to validate our results.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e22500
A preliminary study of apatinib in Chinese patients with osteosarcoma.
E22500 Background: Osteosarcoma is the most common malignant tumor of bone that displays hyperproliferative characteristics and high vascularity, making vascular endothelial growth factor receptors (VEGFRs) become promising targets. Apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, shows anti-cancer effects against a broad range of malignancies. This study reported the clinical experience of apatinib in osteosarcoma. Methods: We collected the medical data of osteosarcoma cases who received apatinib for at least one month in our hospital. The objective response rate (ORR), disease control rate (DCR), and 6-month progression-free survival (PFS) and overall survival (OS) rates were evaluated, and the safety profile was observed. The cut-off date of analysis was 01/17/2017. Results: Between May 2015 and Nov 2016, a total of 34 cases received apatinib with informed consent (4 as neoadjuvant, 1 as neoadjuvant and first line, 10 as first line, 15 as second line and 4 as third line). Among them, 18 (52.9%) cases suffered from pulmonary metastases before apatinib administration; 29 (85.3%) patients had an Eastern Cooperative Oncology Group performance status of 1–2. Initial dosages of 250, 425, and 500 mg/d were given to 5 (14.7%), 3 (8.8%), and 26 (76.5%) cases, respectively. Dosage adjustment occurred in only 8 (23.5%) patients. The median duration was 5.9 months (95%CI, 4.5–9.4 months). According to RECIST v1.1, complete response, partial response, stable disease and progressive disease were achieved in 1 (2.9%), 6 (17.6%), 25 (73.5%) and 2 (5.9%) patients, respectively. The ORR was 20.5%, and the DCR was 94.1%. Patients with pulmonary metastases showed a relatively better response to apatinib, as the ORR and DCR were 33.3% and 88.9%, respectively. As for safety analysis, the most 3 common adverse events (AEs) were hand-foot syndrome (HFS) (29, 85.3%), diarrhea (16, 47.1%), and decreased appetite (9, 26.5%). Nine grade III AEs were occurred including 3 HFS, 2 hypertension, 1 diarrhea, 1 oral mucositis, 1 proteinuria and 1 serious peeling. Conclusions: Apatinib seems to be effective in treating osteosarcoma with acceptable safety profile. Perspective clinical studies with adequate sample size are required to validate our results.
- Open Access
- 29 March 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 731
Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
Sarcoma includes some of the most heterogeneous tumors, which make the diagnosis, prognosis and treatment of these rare yet diverse neoplasms especially challenging. Long noncoding RNAs (lncRNAs) are important regulators of cancer initiation and progression, which implies their potential as neoteric prognostic and diagnostic markers in cancer, including sarcoma. A relationship between lncRNAs and sarcoma pathogenesis and progression is emerging. Recent studies demonstrate that lncRNAs influence sarcoma cell proliferation, metastasis, and drug resistance. Additionally, lncRNA expression profiles are predictive of sarcoma prognosis. In this review, we summarize contemporary advances in the research of lncRNA biogenesis and functions in sarcoma. We also highlight the potential for lncRNAs to become innovative diagnostic and prognostic biomarkers as well as therapeutic targets in sarcoma.
- 29 March 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (4) , 731
Open AccessPotentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
Sarcoma includes some of the most heterogeneous tumors, which make the diagnosis, prognosis and treatment of these rare yet diverse neoplasms especially challenging. Long noncoding RNAs (lncRNAs) are important regulators of cancer initiation and progression, which implies their potential as neoteric prognostic and diagnostic markers in cancer, including sarcoma. A relationship between lncRNAs and sarcoma pathogenesis and progression is emerging. Recent studies demonstrate that lncRNAs influence sarcoma cell proliferation, metastasis, and drug resistance. Additionally, lncRNA expression profiles are predictive of sarcoma prognosis. In this review, we summarize contemporary advances in the research of lncRNA biogenesis and functions in sarcoma. We also highlight the potential for lncRNAs to become innovative diagnostic and prognostic biomarkers as well as therapeutic targets in sarcoma.
- Open Access
- 1 January 2015
- Published by Wiley in Journal of Nanomaterials
- Vol. 2015 (1)
Interim Clinical Outcomes in Nanocomposite Bone Material Repairing Large Proximal Femoral Defect of Fibrous Dysplasia
Background and Objectives. To evaluate the clinical effectiveness and safety of using nanocomposite bone material in the repair of large proximal femoral defects that are due to fibrous dysplasia. Method. Thirty‐one patients were analyzed retrospectively, including 13 males and 18 females, and the mean age was 30.9 years (13–59). The median follow‐up period was 50 months (30–78) and the masses of artificial bone transplants were in the range of 15~40 g (average of 23.4 g). Functional and radiographic outcomes were evaluated. Results. All wounds healed to grade A. There were no infections, nonspecific inflammatory reactions, rejection reactions, or fractures. One case had fat liquefaction and healed after dressing. All patients had no recurrence until the last follow‐up. At the last follow‐up, the mean Musculoskeletal Tumor Society’s (MSTS) 93 score was 28.42 ± 1.31, the mean Harris hip score was 84.23 ± 8.97, and mean radiopaque density ratio was 0.78 ± 0.09. Radiologic analysis indicated that nanocomposite bone material had been completely incorporated with the host bone within a year. Conclusions. This study indicated that the nanocomposite bone material had biological safety and good biocompatibility. In conclusion, the nanocomposite bone material is an ideal artificial bone substitute and worthy of promotion in the field of orthopedics.
- 1 January 2015
- Published by Wiley in Journal of Nanomaterials
- Vol. 2015 (1)
Open AccessInterim Clinical Outcomes in Nanocomposite Bone Material Repairing Large Proximal Femoral Defect of Fibrous Dysplasia
Background and Objectives. To evaluate the clinical effectiveness and safety of using nanocomposite bone material in the repair of large proximal femoral defects that are due to fibrous dysplasia. Method. Thirty‐one patients were analyzed retrospectively, including 13 males and 18 females, and the mean age was 30.9 years (13–59). The median follow‐up period was 50 months (30–78) and the masses of artificial bone transplants were in the range of 15~40 g (average of 23.4 g). Functional and radiographic outcomes were evaluated. Results. All wounds healed to grade A. There were no infections, nonspecific inflammatory reactions, rejection reactions, or fractures. One case had fat liquefaction and healed after dressing. All patients had no recurrence until the last follow‐up. At the last follow‐up, the mean Musculoskeletal Tumor Society’s (MSTS) 93 score was 28.42 ± 1.31, the mean Harris hip score was 84.23 ± 8.97, and mean radiopaque density ratio was 0.78 ± 0.09. Radiologic analysis indicated that nanocomposite bone material had been completely incorporated with the host bone within a year. Conclusions. This study indicated that the nanocomposite bone material had biological safety and good biocompatibility. In conclusion, the nanocomposite bone material is an ideal artificial bone substitute and worthy of promotion in the field of orthopedics.